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Drug–drug interactions are a major concern with tri-
azoles. Azoles are potent metabolic inhibitors and 
interactions commonly occur via metabolizing enzymes 
(ie, cytochrome P450 isoenzyme superfamily) or drug 
transporters (ie, P-glycoprotein). However, the clinical 
relevance of these interactions may vary upon the azole 
involved and upon the “target” drug. Azoles may also 
be under inﬂuence of and become targets of metabolic 
drug–drug interactions. Potential interactions between 
antifungal agents and over-the-counter or alternative 
medicines and herbs should not be underestimated. 
Here, we provide a comprehensive overview of differ-
ent types of pharmacokinetic drug interactions involving 
azoles with selected examples.
Introduction
Antifungal drugs have a high potential for drug–drug 
interactions, especially azoles, which exhibit a wide 
range and variety of drug–drug interactions. This is an 
ongoing concern in the treatment of fungal infections. 
Azoles are well known to inhibit different cytochrome 
P450 (CYP450) enzyme systems, with CYP3A4 being the 
major enzyme involved, but are also a substrate to these 
enzymes. They also are inhibitors of membrane transport-
ers, such as P-glycoprotein (P-gp). Inhibition or induction 
of CYP450 enzymes may alter the pharmacokinetic pro-
file of the drugs involved and can affect both interacting 
members and, in most cases, must be avoided as this 
can lead to overdosing with the consequence of toxicity 
or underdosing with a loss of effectiveness. The risk of 
azole interactions with other drug classes can differ sub-
stantially between individual drugs, even within the same 
class of drugs. 
In general, it is almost impossible for the clinician to 
be aware of all interaction mechanisms and potential con-
sequences for the individual patient. Not all interactions 
are clinically relevant, and a thorough understanding of 
the mechanisms of drug interaction provides the clinician 
with the ability to predict such interactions and to avoid 
those of greatest clinical significance. Regular interaction 
checks by a clinical pharmacist may aid in solving the 
problem of drug interactions. Moreover, the avoidance of 
drug–drug interactions should be regarded as a multidisci-
plinary task. Now, software tools are available facilitating 
rapid interaction checks and providing information on the 
mechanism and clinical relevance of an interaction assist-
ing in the clinical decision making. 
This article reviews a subset of pharmacokinetic drug 
interactions of azoles used in the treatment of systemic 
fungal infections: fluconazole, itraconazole, voriconazole, 
and posaconazole. Consequently, despite its high level of 
metabolic inhibition and drug–drug interactions, keto-
conazole is not addressed in this review. 
Mechanisms of Drug Interaction
Drug interactions can be categorized as pharmacokinetic 
or pharmacodynamic. Pharmacokinetic interactions occur 
at the level of drug absorption, distribution, metabolism or 
excretion. Frequently, the CYP450 metabolizing enzyme 
system and drug transporters, such as P-gp, are involved 
in these interactions. The results of these interactions can 
be a decreased or an increased exposure of both interact-
ing drugs, which, in turn, can lead to reduced efficacy or 
increased toxicity, respectively. Pharmacokinetic drug 
interactions are manageable using dose adaptation, eventu-
ally supported by therapeutic drug monitoring (TDM). 
Pharmacodynamic interactions are those where the 
pharmacological response to a drug is directly altered 
without a change in pharmacokinetic properties. This 
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means that pharmacodynamic interactions are directly 
related to the desired or undesired drug effects. This can 
lead to potentiation of effect (including toxicity) in either 
an additive or synergistic manner, or antagonism. The 
clinical management of pharmacodynamic drug interac-
tions in our opinion has to be to reevaluate the choice 
of the coprescribed drug, achieving the best benefit–risk 
ratio on an individual basis. 
Mechanisms involved in pharmacokinetic drug 
interactions with selected examples are outlined in the 
following sections.
Drug Absorption
All four antifungal drugs discussed in this review can be 
given orally and require absorption through the mucous 
membranes of the gastrointestinal tract. A change in 
plasma concentrations can be the result of incomplete 
drug absorption. Drug absorption of azoles is influenced 
by acid-lowering drugs (such as H2-antagonists and pro-
ton pump inhibitors); food may exert an effect on the 
bioavailability of these drugs as well. Pharmacokinetics 
and bioavailability of fluconazole are not affected by food 
or acid-lowering drugs. 
However, the concomitant administration of itracon-
azole and proton pump inhibitors or H2-antagonists leads 
to impaired absorption, yielding a decrease in exposure [1]. 
Systemic bioavailability of itraconazole capsules is optimized 
when taken with food whereas bioavailability of itraconazole 
oral solution is optimized under fasting conditions [1].
Voriconazole’s pharmacokinetic profile is not influenced 
by antacids or proton pump inhibitors. However, mean 
maximum plasma concentrations (Cmax) and area under 
the curve (AUC) of voriconazole were (clinically irrelevant) 
increased by 15% by omeprazole due to the inhibition of 
plasma clearance of voriconazole [2]. Single and multiple 
oral administration of voriconazole with food lowered the 
bioavailability by approximately 22% and delayed absorp-
tion compared with a fasting state [3]. Administration of 
voriconazole with a high-fat meal reduced mean Cmax and 
AUC by 34% and 24%, respectively. For this reason, oral 
dose administration is recommended either 1 hour before 
or 1 hour after meals [4].
Posaconazole’s Cmax and AUC were reduced by 39% 
when coadministered with cimetidine (400 mg twice 
daily) due to reduced absorption possibly secondary to a 
decrease in gastric acid production. The effects of other 
H2-receptor antagonists (eg, famotidine, ranitidine) and 
proton pump inhibitors (eg, omeprazole) that may sup-
press gastric acidity for several hours on plasma levels of 
posaconazole has not been studied but a reduction in bio-
availability may occur so that co-administration should be 
avoided if possible [5]. In the fasting state, antacid slightly 
increased the relative oral bioavailability of posaconazole 
by 15%. In the nonfasting state, antacids decreased the 
relative bioavailability of posaconazole by 12% [5,6].
The mean increases in posaconazole AUC and Cmax 
values were about 400% when administered with a high-
fat meal compared with the fasting state. Administration 
of the suspension with a nonfat meal enhanced exposure, 
resulting in an increase in AUC by 264% and in Cmax by 
296%, relative to the fasting state [6,7]. Coadministration 
of posaconazole with a nutritional supplement increased 
the Cmax and AUC 340% and 260%, respectively, 
compared with those for the fasting state. Exposure to 
posaconazole when given with a nutritional supplement is 
similar to that when given with a regular meal [8]. 
The gastric pH and the gastrointestinal cell wall com-
position are important in the absorption of antifungal 
drugs. Posaconazole absorption appeared to be reduced in 
patients with grade 1 to 2 mucositis compared with that 
of patients without mucositis (AUC 4.54 mg*h/L vs 8.85 
mg*h/L for twice daily 400 mg posaconazole) [9]. 
Drug Transporters
In addition to CYP enzymes, active transporters, such as P-
gp, organic anion-transporting polypeptides (OATP), and 
breast cancer resistant protein (BCRP), play an important 
role in drug interactions. These active drug transporters 
regulate the access of drugs to the drug-metabolizing 
enzymes and control drug concentrations in enterocytes 
and hepatocytes. A contribution of efflux transporters in 
drug–drug interactions cannot be excluded [10,11]. 
Coadministration of azoles with P-gp substrates is 
known to cause an effect [10]. Two of these azoles, itra-
conazole and posaconazole, are substrates and inhibitors 
of the MDR-1 gene product P-gp [5,11]. Much of the data 
on the effects of the antifungal agents on P-gp comes from 
in vitro cell culture models of directional drug transport 
or ex vivo models of intestinal drug secretion. The results 
obtained seem to vary with the model used, making a 
definitive conclusion difficult. In vivo, no concrete rela-
tions between azoles and P-gp have been established [10].
OATP1B1 is a multispecific carrier capable of bidirec-
tional transport across the sinusoidal liver membrane [12]. 
This specific enzyme is involved in the transport of dif-
ferent drugs. It is suggested that itraconazole might block 
transport of atorvastatin due to inhibition of the OATP1B1 
enzyme system [13]. However, the exact role of OATP has 
not been established, and thus, its specific role remains 
unclear and needs to be investigated. 
BRCP belongs to the adenosine triphosphate–binding 
cassette transporter family. It is expressed in the apical mem-
brane of the epithelium in the small intestine and the liver 
canalicular membrane. It is highly likely that BCRP is inhib-
ited by itraconazole but is not inhibited by fluconazole and 
voriconazole [14]. Thus, BCRP could play a significant role in 
the pharmacokinetic interactions of itraconazole with BCRP 
substrate drug. The relationship between posaconazole and 
BRCP has not been investigated. In vivo, no concrete rela-
tions between azoles and BCRP have been established. 
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Metabolism 
The major site of drug metabolism is the liver, where two 
types of reactions occur. Metabolism of most drugs occurs 
via phase 1 reactions (oxidation, reduction, and hydrolysis). 
The most important enzymes involved in phase 1 reactions 
are the CYP450 enzymes. In addition, phase 2 reactions are 
not mediated by CYP enzymes but involve conjugation of the 
drugs. Drugs can be substrates, inducers, and inhibitors. Sub-
strates are moieties that undergo metabolism by one or more 
CYP enzymes. Enzyme induction can lead to an increased 
(in case of the use of a prodrug) and a decreased drug effect 
whereas enzyme inhibitors decrease the amount of enzyme 
activity. It may take days up to 2 to 3 weeks, depending on 
the drug and its dosage, to fully develop enzyme induction. 
In contrast to induction, enzyme inhibition can occur almost 
immediately. The effect of the drug on the CYP enzyme 
is concentration-dependent. The CYP group of enzymes 
can be highly substrate-specific and, therefore, capable of 
metabolizing only few substrates. They also may be aspecific 
and capable of metabolizing a broad range of substrates. The 
degree of enzyme specificity greatly affects the outcome of 
its inhibition. The broader the enzyme specificity, the more 
drug interactions its inhibition is likely to elicit. 
Effect of Azoles on Comedicated Drugs
All azoles are inhibitors of the CYP3A4 isoenzyme. In 
humans, CYP3A has the largest fraction of the total CYP 
content and is responsible for the metabolism of a broad 
spectrum of drugs. For instance, HMG-CoA reductase 
inhibitors, calcium-channel blockers, and immunosuppres-
sant drugs are known substrates of CYP3A4. Furthermore, 
CYP3A4 is located in the small bowel and liver and, 
therefore, is involved in presystemic (first-pass) metabo-
lism, thus influencing the absorption of CYP3A substrates 
in the gastrointestinal tract. The inhibiting potencies of 
the azoles are vastly different. Itraconazole is considered 
a more potent inhibitor of CYP3A4 than posaconazole 
and voriconazole, which in turn, are more potent than 
fluconazole. Next to CYP3A4, fluconazole, itraconazole, 
and voriconazole have inhibiting potencies for various 
other isoforms, such as CYP2C9 and CYP2C19 [15–17]. 
The clinical relevance will depend on the CYP isoforms 
that metabolize the coadministered drug, the intrahepatic 
concentration of the antifungal agent, and the potency of 
the antifungal agent as an inhibitor of the isoforms that 
metabolize the coadministered drug and vice versa. 
Oral anticoagulants
Understandably, drug interactions with oral antico-
agulants are always of concern, especially when they are 
combined with antifungal drugs. Several interactions 
between azoles and anticoagulants have been reported 
[15,18,19]. There is an increased risk of bleeding in 
patients taking concomitant azoles and anticoagulants. 
Therefore, in general, it is recommended to monitor coag-
ulation variables (international normalized ratio) when 
initiating and stopping azole therapy. 
Immunosuppressant drugs
Calcineurin inhibitors (cyclosporine and tacrolimus) and 
proliferation signal inhibitors (sirolimus and everolimus) 
are substrates of CYP3A4 and substrates and inhibitors 
of P-gp. As a consequence, they have immense potential 
for clinically significant drug interactions that result in 
increased whole-blood concentrations of the immunosup-
pressant drug. 
Cyclosporine–fluconazole interaction is controversial 
and may result in a nonclinically relevant increase of con-
centration of cyclosporine [20,21], whereas concomitant 
administration of voriconazole and cyclosporine resulted 
in a 1.7- to 2.5-fold increase of cyclosporine [22]. The 
effect of itraconazole showed a mean 80% increase of 
cyclosporine concentration [23,24]. This interaction effect 
is based on the intravenous admixtures of itraconazole 
and cyclosporine. The effect of oral formulations might 
be more extensively due to inhibition of mucosal CYP 
enzymes. Posaconazole was the least potent inhibitor of 
cyclosporine, resulting in an increase of AUC of 30% 
(range 20.7–27.3 ng*h/mL). The effect of the interaction 
may be limited because of the low dose of posaconazole 
administered (200 mg once daily). It is not known whether 
higher doses would yield a stronger effect. 
Tacrolimus’s pharmacokinetic profile is influenced 
in a similar qualitative-profile way as cyclosporine but 
exhibits higher intensities. Posaconazole increased the 
Cmax and AUC for tacrolimus by 121% and 358%, 
respectively, on day 14 compared with day 1 [24,25]. A 
case report described a 3.5-fold increase of tacrolimus 
when combined with voriconazole [26]. Fluconazole 
exerts a significant effect on tacrolimus resulting in a 
twofold increased exposure. Itraconazole represents a 
potent inhibitor of tacrolimus metabolism varying from 
twofold in renal transplant patients up to fivefold in lung 
transplant patients; therefore, this association must be 
carefully monitored [24,27,28].
Sirolimus’s pharmacokinetics are strongly affected by 
voriconazole [29], and a decrease of 90% of sirolimus dos-
age was necessary to avoid toxicity. No randomized studies 
with fluconazole, itraconazole, or posaconazole and siroli-
mus have been performed to assess the interaction. In two 
case reports, there was a significant influence on sirolimus’s 
AUC and Cmax, caused by fluconazole and itraconazole 
[30,31]. An effect of posaconazole is to be expected. 
Only one case report has been published on the 
interaction between everolimus and fluconazole and itra-
conazole. Azoles were represented by fluconazole in 16 
patients and itraconazole in one patient. Data suggested 
no significant influence from fluconazole, but a potentially 
large influence from itraconazole, on everolimus [32]. The 
patient receiving concomitant itraconazole and everolimus 
exhibited a 74% decrease in clearance of everolimus. No 
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published data are available for voriconazole or posacon-
azole, but such interactions are very likely, and special 
caution is recommended during coprescription.
Based on these results, it is recommended to reduce 
the dose of cyclosporine and tacrolimus when coadmin-
istered with azoles under careful TDM. The combined 
use of sirolimus with voriconazole must be avoided but 
fluconazole can be given simultaneously with frequent 
monitoring of sirolimus whole-blood concentrations. Itra-
conazole should be used with extreme caution only and 
with careful TDM. Concomitant administration of potent 
inhibitors of CYP3A may decrease the clearance of evero-
limus and increase its blood levels. Frequent monitoring 
of everolimus is recommended. 
Benzodiazepine sedative drugs
Coadministration of all azoles with midazolam results in 
significant pharmacokinetic interactions and alterations 
in the pharmacodynamics of this agent [33,34,35•]. The 
combination of azoles and midazolam must be avoided, 
or midazolam dosage must be reduced and patients must 
have a clinical follow-up when on intravenous therapy. 
Also other benzodiazepine drugs, such as diazepam, are 
influenced by fluconazole, itraconazole, and voricon-
azole [36,37]. No data are available for posaconazole but 
because diazepam is metabolized by CYP2C19, a relevant 
effect is not to be expected. 
Anticancer drugs
Voriconazole, posaconazole, and itraconazole are known to 
interfere with vincristine metabolism and increase its neu-
rotoxicity [38,39•,40•,41]. Enhanced toxicity is due to the 
inhibition of CYP450-mediated metabolism of vincristine, 
leading to increased plasma levels of the drug. Itraconazole 
also inhibits the P-gp efflux pump, which is responsible for 
increasing the excretion of vinca alkaloids from the cell, 
resulting in high intracellular vincristine levels. Marr et al. 
[42] found that itraconazole and fluconazole alter metabo-
lism of cyclophosphamide in unique fashions, potentially 
impacting toxicities early after stem cell transplantation. 
Enhancement of taxane toxicities is also reported with 
CYP inhibitors and caution should be required with azoles 
as well [1]. These observations are sufficient to encourage 
caution with coadministration of azoles and cytochrome-
metabolized cytotoxic agents because coadministration of 
azoles might interfere with the curative therapy. 
Effect of Comedicated Drugs on Azoles
Fluconazole is mainly excreted unchanged in urine and, thus, 
not under influence of induction or inhibition of a metabolic 
pathway. Interactions influencing the pharmacokinetic 
profile of fluconazole through this system are not likely. 
Itraconazole and voriconazole are metabolized by the liver 
via phase 1 reactions with different isoenzymes involved as 
the major metabolic pathway. Itraconazole is predominantly 
metabolized by CYP3A4 and is the only azole with an active 
metabolite [43,44], whereas voriconazole is substrate to 
CYP2C19 and to a lesser extent CYP2C9 and CYP3A4. 
Posaconazole metabolism involves phase 2 reactions [45] 
(glucuronidation of the drug) (Table 1). Drugs influenc-
ing this phase 2 enzyme systems can exert a change in the 
pharmacokinetic profile of the azole involved leading to an 
increased or decreased exposure. 
Drug inducers, such as phenytoin and rifampicin, may 
cause a clinically significant alteration in pharmacokinetic 
behavior of itraconazole, voriconazole, and posaconazole 
[46–48]. Repeated dose administration of phenytoin 
decreased the mean steady-state Cmax and AUC of vori-
conazole by approximately 50% and 70%, respectively 
[46]. Increasing the dose of voriconazole from 200 mg 
to 400 mg twice daily compensated for this effect. The 
interaction is a two-way interaction because phenytoin’s 
pharmacokinetics are affected by voriconazole with an 
increase of the mean steady-state Cmax and AUC of phe-
nytoin by approximately 70% and 80%, respectively [46]. 
Table 1. Metabolism of azole antifungals
Enzyme system Fluconazole Itraconazole Posaconazole Voriconazole
Inhibitor
2C9 ++* + – ++
2C19 + – – +++
3A4 ++ +++ +++ ++
P-glycoprotein – Yes Yes –
Substrate
2C9 – – – +
2C19 – – – +++
3A4 – +++ – +
P-glycoprotein – Yes Yes –
*Plus signs (+) indicate the severity of inhibition or induction.
(Data from Wang et al. [11] and Saad et al. [62••].)
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Coadministration of posaconazole with phenytoin resulted 
in 44% and 52% decreases in posaconazole Cmax and 
AUC, respectively [49]. 
Because coadministration of enzymatic inducers, such 
as phenytoin and rifampin, significantly reduces expo-
sure of azoles, concomitant use of these agents should 
be avoided unless the benefit outweighs the risk. Because 
fluconazole is mainly excreted by the kidneys and not 
metabolized hepatically, it is not under significant influ-
ence of enzyme inducers and, thus, could be considered 
as a therapeutic option in case of appropriate indication, 
such as a candidiasis. 
Also, HIV protease inhibitors (eg, ritonavir) and non-
nucleoside reverse transcriptase inhibitors (eg, efavirenz) 
cause a clinically significant change in azole exposure 
[50,51,52•,53,54•]. The interaction between voricon-
azole and efavirenz is considered a two-way interaction 
because both voriconazole and efavirenz are affected 
when coadministered [54•]. Enzymatic inhibitors, such 
as erythromycin and clarithromycin, may play a signifi-
cant role in drug interactions and should be considered 
for azole inhibition. Inhibition could enhance the risk of 
azole toxicities, especially hepatotoxicity [55].
TDM comprises the measurement and interpretation 
of drug concentrations in biological fluids to assist in the 
determination of drug dosage for the individual patient. 
TDM integrates dose, concentration, and effect in order 
to understand more precisely the pharmacokinetics and 
pharmacodynamics of the drug in an individual. The risk 
of subtherapeutic concentrations due to induction of the 
metabolic turnover of azoles is an indication for TDM. 
When TDM yields subtherapeutic levels, the dose of the 
specific drug involved can be increased. This should improve 
response to therapy, and thus be considered a tool to manage 
drug–drug interactions and prevent therapeutic failure. 
Genetic Polymorphism 
of CYP450 Enzyme Systems
The main CYP450 enzymes involved in the metabo-
lization of azoles include CYP2C9, CYP2C19, and 
CYP3A4/3A5. All enzymes are known to have multiple 
polymorphisms that divide the general population into 
poor (PM) and extensive metabolizers (EM). Polymor-
phisms of CYP2C9 and CYP2C19 may play a clinically 
relevant role in the pharmacokinetics of selected azoles. 
In homozygous PMs of CYP2C19, the Cmax and AUC of 
voriconazole are approximately two to five times higher 
than for EMs [56]. By blocking the CYP3A4 pathway 
through administration of ritonavir in PM homozygous 
patients, voriconazole exposure can increase up to 800% 
compared with wild-type genotype [56]. The CYP2C9 
genotypic variation does not influence the exposure to 
voriconazole [57] as only a small fraction of the drug 
is metabolized through this enzymatic pathway. The 
prevalence of variations in the gene sequence differs by 
race [58]. Assessing the genotype of patients may predict 
possible toxicity especially in Asian patients who may be 
at risk because the frequency of PMs is higher resulting 
in higher plasma concentrations and toxicity. TDM may 
be used as a tool to determine high exposure to azoles. 
When TDM yields high concentrations the genotype may 
be assessed in order to determine the cause of the high 
concentration of voriconazole. Determining the patient’s 
genotype before initiation of therapy is not recom-
mended; rather, using clinical signs to determine toxicity 
together with monitoring of plasma concentrations is 
more suitable. On the contrary, a drug interaction study 
can be more valuable if performed with the knowledge 
of patients’ genotypic status. 
Excretion
Drug interactions based on alterations in renal elimination 
mainly involve changes in tubular secretion or changes in 
kidney function. Drugs that use the same active transport 
system in the kidney tubules can compete for this excretory 
system. The two drugs excreted by the kidneys are fluco-
nazole and hydroxyitraconazole. No interaction reports 
have been published dealing with impaired renal function 
caused by nephrotoxic drugs, such as cyclosporine or gen-
tamicin, leading to increased exposure of fluconazole or 
hydroxyitraconazole and, thus, increased toxicity. 
Over-the-counter and Alternative Medicines
The risks associated with alternative (herbal) medicines, 
over-the-counter products (eg, vitamins, NSAIDs), and 
nutritional supplements when used in combination with 
antifungals are of most concern. Most of these interac-
tions are grossly under-reported. Widespread use of these 
products and a perceived lack of awareness of risk could 
confront the patient and their doctor with sudden, unex-
pected toxic effects or loss of efficacy. Typical examples 
include the use of St. John’s wort and grapefruit juice. 
Coadministration of grapefruit juice and itraconazole 
produced a statistically significant, but clinically irrele-
vant, increase in itraconazole oral solution AUC of 17%. 
Apparent oral clearance of itraconazole oral solution was 
significantly reduced (14%) which is caused by inhibition 
of intestinal CYP3A4 [59]. Concurrent use of grapefruit 
juice and itraconazole capsules resulted in an even stron-
ger effect: a 43% decrease in the mean itraconazole AUC 
and a 47% decrease in the mean hydroxyitraconazole 
AUC. It can be concluded that concomitant grapefruit 
juice does not enhance the systemic availability of itra-
conazole capsules but appears to impair its absorption. 
Therefore, the use of grapefruit juice will be most likely 
to yield subtherapeutic concentrations of itraconazole 
[60]. No recommendations have been made on the 
concomitant use of fluconazole or voriconazole with 
grapefruit juice, but an effect, based on the metabolism 
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of the drugs, is most likely not to occur or, at least, not 
be clinically relevant. The effect of grapefruit juice on 
posaconazole remains to be determined. 
St. John’s wort had a clinically significant effect 
on voriconazole exposure. After an initial, clinically 
irrelevant, increase of voriconazole AUC, there was a sig-
nificant 59% decrease in exposure of voriconazole [61]. 
The use of St. John’s wort is, therefore, contraindicated 
when on voriconazole therapy. 
The risk of combined use of alternative or over-the-
counter medicines with azoles will be occasional and 
intermittent, but most of all, intake is unknown to the 
treating physician, thus complicating the diagnosis of 
a drug interaction. When considering drug interactions 
with alternative and over-the-counter medicines, it is not 
possible to propose a contraindication in the case of a 
nonregistered substance, and therefore, we are not able 
to warn patients on possible risks in case of concomitant 
use of these products with their antifungal treatment. 
Conclusions
Drug interactions can cause many clinical problems. 
Metabolic inhibitory effects of azoles are very potent, 
will yield higher exposure to the coadministered drug 
and may cause great difficulties in establishing a good 
therapy due to toxicity. 
Ideally, all of this knowledge should be available before 
a new drug enters clinical testing. Although translation of 
preclinical data to the clinic remains cumbersome and will 
never be perfect, we should always aim for the maximum 
attainable therapeutic effect. Therefore, it is important to 
continue the collection of more mechanistic and theoreti-
cal knowledge about drug interactions. 
One should also bear in mind that a drug interaction 
not only occurs upon initiation of therapy but might also 
become evident when a drug is stopped. Common knowl-
edge is the key factor. 
Awareness of the mechanisms involved in these 
interactions is pivotal in the optimization of treat-
ment of patients requiring antifungal therapy, together 
with clinical relevance in terms of severity and scien-
tific documentation, will result in a strategy to safely 
manage coprescriptions and to establish the level of 
recommendation associated with the drug interaction 
(contraindicated, not recommended, warning). Address-
ing drug–drug interactions is a multidisciplinary task 
with the goals to minimize unwanted side effects in 
patients and optimize patient care, and TDM should be 
considered in the optimization of such pharmacokinetic 
drug–drug interactions.
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